Table 2.
Comparison of dosimetric parameters from treatment plans obtained in the two setup positions for the whole patients series (41 patients)
| Prone setup | Supine setup | p-value | |
|---|---|---|---|
| PTV (cc) |
534.9 ± 229.4 |
515.3 ± 174.2 |
0.32 |
| V95 (%) |
96.5 ± 3.5 |
98.0 ± 1.6 |
0.04 |
| V105 (%) |
1.4 ± 1.1 |
2.0 ± 2.5 |
0.14 |
| V107 (%) |
0.1 ± 0.2 |
0.2 ± 0.5 |
0.16 |
| Dmin (Gy) |
35.8 ± 11.3 |
35.8 ± 10.2 |
0.97 |
| Dmax (Gy) |
53.7 ± 0.6 |
53.7 ± 0.6 |
0.80 |
| Dmean (Gy) |
50.1 ± 0.4 |
50.1 ± 0.3 |
0.42 |
| CTV (cc) |
468.1 ± 216.6 |
432.0 ± 159.0 |
0.02 |
| V95 (%) |
98.4 ± 2.3 |
99.3 ± 1.0 |
0.02 |
| V105 (%) |
1.3 ± 1.1 |
1.8 ± 2.4 |
0.25 |
| V107 (%) |
0.1 ± 0.2 |
0.1 ± 0.4 |
0.45 |
| Dmin (Gy) |
42.4 ± 7.4 |
44.4 ± 4.4 |
0.15 |
| Dmax (Gy) |
53.6 ± 0.6 |
53.5 ± 0.6 |
0.42 |
| Dmean (Gy) |
50.2 ± 0.4 |
50.2 ± 0.3 |
0.92 |
| Lung (cc) |
1335.0 ± 331.0 |
1201.0 ± 264.0 |
<10-6 |
| V20 (%) |
1.5 ± 1.8 |
9.0 ± 3.4 |
<10-6 |
| V10 (%) |
2.6 ± 2.4 |
12.7 ± 4.3 |
<10-6 |
| V5 (%) |
4.0 ± 3.2 |
18.4 ± 5.3 |
<10-6 |
| Dmean (Gy) |
1.4 ± 0.9 |
5.2 ± 1.5 |
<10-6 |
| Dmax (Gy) | 39.7 ± 12.4 | 49.5 ± 1.7 | <10-5 |
PTV, planning target volume; CTV, clinical target volume.